Neoadjuvant hormonanl therapy before radiation for prostate cancer – pro
Several randomized studies compared combination treatment with radiotherapy only and adjuvant ADT Results improved especially in patients with a moderate or high risk profile. For the former, short-term ADT lead to significantly more instances of biochemical absence of recurrence and PCSM. For locally limited prostate cancer with risk factors, two studies found a benefit for short-term ADT for four to six months in addition to radiotherapy compared with radiotherapy alone for all relevant endpoints (bNED, PCSM, and OS). Other supportive studies come from he Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC) in high-risk patients with positive results. NCCN guideline support neoadjuvant hormonal therapy before radiation
Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107–118.
Dirk Böhmer et al,The Use of Combined External Beam Radiotherapy and Hormonal Therapy in the Management of Localized and Locally Advanced Prostate Cancer Dtsch Arztebl Int. 2016 Apr; 113(14): 235–241.